Curis Downgraded by Zacks to “Neutral” (CRIS)
Curis (NASDAQ:CRIS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued on Wednesday, AR Network reports. They currently have a $4.90 target price on the stock. Zacks‘ target price suggests a potential upside of 27.27% from the stock’s previous close.
Shares of Curis (NASDAQ:CRIS) traded down 0.52% on Wednesday, hitting $3.83. The stock had a trading volume of 788,100 shares. Curis has a 1-year low of $2.66 and a 1-year high of $4.74. The stock has a 50-day moving average of $4.3 and a 200-day moving average of $3.79. The company’s market cap is $312.9 million.
Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.02) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.03. The company had revenue of $5.40 million for the quarter, compared to the consensus estimate of $4.43 million. During the same quarter last year, the company posted ($0.04) earnings per share. Curis’s revenue was up 22.7% compared to the same quarter last year. On average, analysts predict that Curis will post $-0.16 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird initiated coverage on shares of Curis in a research note to investors on Tuesday, October 1st. They set an “outperform” rating and a $7.00 price target on the stock. Separately, analysts at Chardan Capital initiated coverage on shares of Curis in a research note to investors on Monday, September 30th. They set a “buy” rating and a $6.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Curis from $6.00 to $7.00 in a research note to investors on Wednesday, August 14th. They now have an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Curis currently has an average rating of “Buy” and a consensus price target of $6.23.
Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.